Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

Financials ($)
Sales 2016 67,9 M
EBIT 2016 3,97 M
Net income 2016 -9,56 M
Debt 2016 49,8 M
Yield 2016 -
Sales 2017 94,7 M
EBIT 2017 13,3 M
Net income 2017 -0,31 M
Debt 2017 60,2 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 6,79x
EV / Sales2017 4,98x
Capitalization 411 M
More Financials
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
10/20Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
09/13 TELIGENT, INC. : To Present At Morgan Stanley Global Healthcare Conference On Se..
09/01 TELIGENT : Announces Health Canada Approval Of Gentamicin Injection USP
08/25 TELIGENT, INC. : Announces Health Canada Approval Of Three Baclofen Injection Pr..
08/23 TELIGENT, INC. : Announces Health Canada Approval Of Gentamicin Injection USP
08/08 TELIGENT : Management's Discussion and Analysis of Financial Condition and Resul..
08/02 TELIGENT : Sanders Morris Harris buys $15,297,383 stake in Teligent Inc
07/29 TELIGENT : reports 2Q loss
07/28 TELIGENT, INC. : Announces Second Quarter 2016 Results
07/28 TELIGENT, INC. : Results of Operations and Financial Condition, Financial Statem..
07/19 TELIGENT : Advances $50 Million Facility Expansion
More news
Sector news : Pharmaceuticals - NEC
09:39p MYLAN : faces scrutiny over EpiPen profit data shown to Congress
05:36pDJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
05:36pDJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress
04:45pDJPfizer Throws Out Plan to Split Into Two Companies
01:53pDJPFIZER : Won't Pursue a Split of Established and New Medical Lines -- Update
More sector news : Pharmaceuticals - NEC
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 9,75 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Sanjay Samudre Operations Director
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results